CN102497875B - 抑制空肠弯曲杆菌细菌感染的抗原组合物和方法及该抗原组合物的用途 - Google Patents

抑制空肠弯曲杆菌细菌感染的抗原组合物和方法及该抗原组合物的用途 Download PDF

Info

Publication number
CN102497875B
CN102497875B CN201080041149.4A CN201080041149A CN102497875B CN 102497875 B CN102497875 B CN 102497875B CN 201080041149 A CN201080041149 A CN 201080041149A CN 102497875 B CN102497875 B CN 102497875B
Authority
CN
China
Prior art keywords
campylobacter jejuni
flpa
albumen
chicken
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080041149.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102497875A (zh
Inventor
迈克尔·康克尔
泰瑞·唐
查理·拉尔森
詹森·尼尔-麦金尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington State University Research Foundation
Original Assignee
Washington State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington State University Research Foundation filed Critical Washington State University Research Foundation
Publication of CN102497875A publication Critical patent/CN102497875A/zh
Application granted granted Critical
Publication of CN102497875B publication Critical patent/CN102497875B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • G—PHYSICS
    • G10—MUSICAL INSTRUMENTS; ACOUSTICS
    • G10L—SPEECH ANALYSIS TECHNIQUES OR SPEECH SYNTHESIS; SPEECH RECOGNITION; SPEECH OR VOICE PROCESSING TECHNIQUES; SPEECH OR AUDIO CODING OR DECODING
    • G10L13/00—Speech synthesis; Text to speech systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Multimedia (AREA)
  • Acoustics & Sound (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Computational Linguistics (AREA)
  • Audiology, Speech & Language Pathology (AREA)
  • Human Computer Interaction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201080041149.4A 2009-07-16 2010-07-16 抑制空肠弯曲杆菌细菌感染的抗原组合物和方法及该抗原组合物的用途 Expired - Fee Related CN102497875B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22625609P 2009-07-16 2009-07-16
US61/226,256 2009-07-16
PCT/US2010/042262 WO2011009042A2 (en) 2009-07-16 2010-07-16 Antigen compositions and methods of inhibiting campylobacter jejuni bacterial infection and uses of the antigen compositions

Publications (2)

Publication Number Publication Date
CN102497875A CN102497875A (zh) 2012-06-13
CN102497875B true CN102497875B (zh) 2014-08-20

Family

ID=43450236

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080041149.4A Expired - Fee Related CN102497875B (zh) 2009-07-16 2010-07-16 抑制空肠弯曲杆菌细菌感染的抗原组合物和方法及该抗原组合物的用途

Country Status (5)

Country Link
US (1) US9047864B2 (enExample)
EP (1) EP2453909A4 (enExample)
CN (1) CN102497875B (enExample)
IN (1) IN2012DN01214A (enExample)
WO (1) WO2011009042A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180120136A1 (en) * 2016-10-27 2018-05-03 General Electric Company Time-varying flow estimation for virtual flow metering applications
CN110903359B (zh) * 2019-12-23 2021-09-17 杭州贤至生物科技有限公司 一种空肠弯曲菌重组蛋白及其单克隆抗体的制备
CN112094328A (zh) * 2020-09-21 2020-12-18 华南农业大学 一种空肠弯曲杆菌外膜囊泡的提取及纯化方法
CN113144182B (zh) * 2021-04-22 2023-03-10 成都欧林生物科技股份有限公司 一种幽门螺杆菌口服缓释疫苗及其制备与应用
CN118510541A (zh) * 2021-09-20 2024-08-16 生物编辑有限责任公司 多价抗弯曲杆菌抗体和疫苗

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156546A (en) * 1997-05-16 2000-12-05 Washington State University Research Foundation Identification and molecular cloning of a gene encoding a fibronectin binding protein (CadF) from Campylobacter coli and Campylobacter jejuni
WO2005049641A2 (en) * 2003-11-21 2005-06-02 Ace Biosciences A/S Surface-located campylobacter jejuni polypeptides
US20070249553A1 (en) * 2004-10-26 2007-10-25 The Secretary Of State For Environment, Food & Rural Affairs Vaccine And Nucleic Acids Capable Of Protecting Poultry Against Colonisation By Campylobacter

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106159A1 (en) 2003-08-12 2005-05-19 Thompson Stuart A. Campylobacter jejuni outer membrane protein immunogenic composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156546A (en) * 1997-05-16 2000-12-05 Washington State University Research Foundation Identification and molecular cloning of a gene encoding a fibronectin binding protein (CadF) from Campylobacter coli and Campylobacter jejuni
WO2005049641A2 (en) * 2003-11-21 2005-06-02 Ace Biosciences A/S Surface-located campylobacter jejuni polypeptides
US20070249553A1 (en) * 2004-10-26 2007-10-25 The Secretary Of State For Environment, Food & Rural Affairs Vaccine And Nucleic Acids Capable Of Protecting Poultry Against Colonisation By Campylobacter

Also Published As

Publication number Publication date
US20120183570A1 (en) 2012-07-19
US9047864B2 (en) 2015-06-02
CN102497875A (zh) 2012-06-13
IN2012DN01214A (enExample) 2015-04-10
EP2453909A4 (en) 2013-05-01
EP2453909A2 (en) 2012-05-23
WO2011009042A8 (en) 2012-03-08
WO2011009042A3 (en) 2011-05-26
WO2011009042A2 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
Dubreuil et al. Animal enterotoxigenic Escherichia coli
Fairbrother et al. Escherichia coli in postweaning diarrhea in pigs: an update on bacterial types, pathogenesis, and prevention strategies
AU2016222520B2 (en) Attenuated Streptococcus suis vaccines and methods of making and use thereof
WO2020163284A1 (en) A genetically modified lactobacillus and uses thereof
JP2021063084A (ja) タンパク質及びｋｌｅｂｓｉｅｌｌａタンパク質を含有する免疫化組成物ならびにその使用方法
CN102497875B (zh) 抑制空肠弯曲杆菌细菌感染的抗原组合物和方法及该抗原组合物的用途
US20240390433A1 (en) Genetically modified bacillus subtilis strain and use as a live delivery and production system
Velge et al. Variability of Listeria monocytogenes virulence: a result of the evolution between saprophytism and virulence?
US20200040067A1 (en) Anti-salmonella antibodies and uses thereof
KR101684292B1 (ko) 폴리펩티드 및 그람 양성 폴리펩티드를 함유하는 면역 조성물 및 사용 방법
TW201113373A (en) A cytolytic RTX-toxin from gallibacterium anatis
US20220288183A1 (en) Vaccine constructs and uses thereof against staphylococcus infections
Zhou et al. Evaluation of the protective efficacy of four novel identified membrane associated proteins of Streptococcus suis serotype 2
Chen et al. B orrelia p eptidoglycan i nteracting P rotein (BpiP) contributes to the fitness of Borrelia burgdorferi against host-derived factors and influences virulence in mouse models of Lyme disease
Neri et al. Specific egg yolk immunoglobulin as a new preventive approach for Shiga-toxin-mediated diseases
WO2013034682A1 (en) Vaccine based on staphylococcal superantigen- line 3 protein (ssl3)
Cook et al. Orally administered anti-Escherichia coli O157: H7 chicken egg yolk antibodies reduce fecal shedding of the pathogen by ruminants
Jiang et al. FlgN plays important roles in the adhesion of Aeromonas hydrophila to host mucus
Stiles Clostridial binary toxins: basic understandings that include cell surface binding and an internal “Coup de Grâce”
US10166280B2 (en) Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
US11318192B2 (en) Engineered proteins and methods of use
E Webster Investigating iron uptake systems in C. jejuni and C. coli
Łasica et al. Application of a liposomal subunit vaccine in chickens for reduction of Campylobacter gut colonisation
Hartley Characterisation of the Aspartate Chemosensory Receptor of Campylobacter jejuni
Chintoan-Uta Rational design of vaccines for the control of Campylobacter in chickens

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140820

Termination date: 20180716

CF01 Termination of patent right due to non-payment of annual fee